ADVANCES IN LIPOSOMAL DRUG DELIVERY SYSTEM: FASCINATING TYPES AND POTENTIAL APPLICATIONS
Liposomes are an efficient novel drug delivery system. They are used because of their structure which is stable and due to their ability to accommodate both lipophilic and hydrophilic drug. Various fascinating types of liposomes have been developed in recent past to further enhance their utility. Long-circulating liposomes or stealth liposomes are able to hide from the defence system of the body and circulate for a longer time in the blood. Targeted liposomes namely immuno- liposomes consists of antibodies conjugated on their surface to improve the specificity of the cell. Liposomes have been modified as per the conditions of pH and temperature, specifically designed to improve drug delivery to targeted tumor cells. Liposomes are being used in the treatment of various diseases and there are various liposomal drug formulations available today. Liposomes can be used as carriers for genetic materials such as antisense, DNA, RNA which are useful in the treatment of diseases. Liposomes are also efficient carriers of cytokines which further activate macrophages. This review provides the detailed insight of types and applications of liposomes and the potential challenges in the development of liposomal drug delivery systems.
2. Ceh B, Winterhalter M, Frederik PM, Vallner JJ, Lasic DD. StealthÂ® liposomes: from theory to product. Adv Drug Delivery Rev 1997;24:165-77.
3. Klibanov AL, Torchilin VP, Zalipsky S. Long-circulating sterically protected liposomes. In: Liposomes: a practical approach. 2nded. New York: Oxford University Press Inc; 2003. p. 231-63.
4. Leach KJ. Cancer, drug delivery to treat local and systemic. In: Edith Mathiowitz. editor. Encyclopedia of Controlled Drug Delivery. Vol. 1. John Wiley and sons Inc., New York; 1999. p. 119-42.
5. Mizoue T, Horibe T, Maruyama K, Takizava T, Iwatsuru M, Kono K, et al. Targetability and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immuno- liposomes to tumour cells. Int J Pharm 2002;237:129-37.
6. Managit C, Kawakami S, Nishikawa M, Yamashita F, Hashida M. Targeted and sustained drug delivery using PEGylated galactosylated liposomes. Int J Pharm 2003;226:77-84.
7. SÃ¼ss RP, Schubert R. pH-sensitive liposomes. In: Weissig V, Torchillin VP. editors. Liposomes: a practical approach. 2nd ed. New York: Oxford University Press Inc; 2003. p. 305-18.
8. Kono K, Henmi A, Yamashita H, Hayashi H, Takagishi T. Improvement of temperature-sensitivity of poly(N-iso-propylacrylamide)-modified liposomes. J Controlled Release 1999;59:63-75.
9. Fife K, Bower M, Cooper RG, Stewart L, Etheridge CJ, Coombes RC, et al. Endothelial cell transfection with cationic liposomes and herpes simplex-thymidine kinase mediated killing. Gene Ther 1998;5:614-20.
10. Singh M, Ferdous AJ, Jackson TL. Stealth monensin liposomes as a potentiator of adriamycin in cancer treatment. J Controlled Release 1999;59:43-59.
11. Elbialy NS, Mady MM. Ehrlich tumor inhibition using doxorubicin containing liposomes. Saudi Pharm J 2015;23:182-7.
12. Rane S, Prabhakar B. Influence of liposome composition on paclitaxel entrapment and pH sensitivity of liposomes. Int J Pharm Tech Res 2009;1:914-7.
13. Rane S, Prabhakar B. Optimization of paclitaxel-containing pHâ€‘sensitive liposomes by 3 factor, 3 level box-behnken design. Indian J Pharm Sci 2013;75:420-6.
14. Tang J, Zhang L, Fu H, Kuang Q, Gao H, Zhang Z et al. A detachable coating of cholesterol-anchored PEG improves tumor targeting of cell-penetrating peptide-modified liposomes. Acta Pharm Sin B 2014;4:67-73.
15. Immordini ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Controlled Release 2003;91:417-29.
16. Shabnama, Srinivas P, Ravindra Babu DS. Formulation and evaluation of parenteral methotrexate nanoliposomes. Int J Pharm Pharm Sci 2014;6:295-300.
17. Shim G, Yu YH, Lee S, Kim J, Oh YK. Surface-modified liposomes for syndecan 2â€“targeted delivery of edelfosine. Asian J Pharm Sci 2016;II:596-602.
18. Moribe K, Maruyama K, Iwatshuru M. Molecular localization and state of amphotericin B in PEG liposomes. Int J Pharm 1999;193:97-106.
19. Van Etten EWM, Van Vianen W, Tijhuis RHG, Storm G, Woudenberg IAJMB. Sterically stabilized amphotericin B-liposomes" toxicity and biodistribution in mice. J Controlled Release 1995;37:123-9.
20. Borborema SET, Schwendener RA, Osso Junior JA, Andrade Junior HE, Nascimento N. Uptake and antileishmanial activity of meglumine antimoniate-containin liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 2011;38:341-7.
21. Fattal E, Couvreur P, Dubernet C. â€˜â€˜Smartâ€™â€™ delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Delivery Rev 2004;56:931-46.
22. Meissner JM, Toporkiewicz M, Czogalla A, Matusewicz L, Kuliczkowski K, Sikorski AF. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with the anti-CD20 antibody. J Controlled Release 2015;220:515-28.
23. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Berestein GL. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Delivery Rev 2015;87:108-19.
24. De Oliveira MC, Fattal E, Ropert C, Malvy C, Couvreur P. Delivery of antisense oligonucleotides by means of pH-sensitive liposomes. J Controlled Release 1997;48:179-84.
25. Shokrzadeh N, Winkler KM, Dirin M, Winkler J. Oligonucleotides conjugated with short chemically defined polyethylene glycol chains are efficient antisense agents. Bioorg Med Chem Lett 2014;24:5758-61.
26. Peddada L, Garbuzenko OB, Devore DL, Minko T, Roth CM. Delivery of antisense oligonucleotides using poly(alkylene oxide)â€“poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes. J Controlled Release 2014;194:103-12.
27. Lorenzer C, Dirin M, Winkler AM, Baumann V, Winkler J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Controlled Release 2015;203:1-15.
28. Liu J, Wang Z, Li F, Gao J, Wang L, Huang G. Liposomes for systematic delivery of vancomycin hydrochloride to decrease nephrotoxicity: characterization and evaluation. Asian J Pharm Sci 2015;10:212-22.
29. Unida S, Ito Y, Onodera R, Tahara K, Takeuchi H. Inhalation properties of water-soluble drug-loaded liposomes atomized by nebulizer. Asian J Pharm Sci 2016;II:205-6.
30. Jacob JS. Characterization of delivery systems, microscopy. In: Edith Mathiowitz. editor. Encyclopaedia of controlled drug delivery. Vol. 1. John Wiley and sons Inc., New York; 1999. p. 234-49.
31. Nagpala D, Nidhi A, Katarec D. Evaluation of liposomal gossypin in animal models of epilepsy. Int J Pharm Pharm Sci 2016;8:247-51.
32. Shiny A, Toomu M, Dhurke RK. Enhanced dermal delivery of nadifloxacin using liposomes. Int J Appl Pharm 2016;8:53-9.
33. Zuidam NJ, Vrueh R, Crommelin DJA. Characterization of liposomes. In: Weissig V, Torchilin VP. editors. Liposomes: a practical approach. 2nded. New York: Oxford University Press Inc; 2003. p. 31-76.
34. Liposome Drug Products. U. S. Department of Health and Human Services Food and Drug Administration Centre for Drug Evaluation and Research (CDER): Pharmaceutical Quality/CMC; 2015.